Skip to main content

research_finding

Hylenr Technologies Detects Rare-Earth Signatures in Lattice Fusion System

Image
Hylenr Technologies Detects Rare-Earth Signatures in Lattice Fusion System

Hyderabad – September 12, 2026 -- Indian deep-tech firm Hylenr Technologies has detected signatures of 32 elements, including rare-earth species and actinides, forming inside engineered hydrogen-loaded nickel-palladium lattice structures, opening a potential alternative pathway to mining for strategic-material production.

Two years of analysis reveal 32 elemental signatures across light, heavy and noble-gas categories

Over approximately two years of post-operation material analysis, Hylenr Technologies identified signatures corresponding to 32 elements compared against pre-operation baseline samples of the same catalyst material used as a control. The detections span light and heavy elements, noble gases including helium, neon and argon, strategically important rare-earth species such as yttrium, and actinides including uranium.

Isomab Review Clears Cancer, Eye Safety Fears for Angiogenic Heart Therapies

Image
Isomab Review Clears Cancer, Eye Safety Fears for Angiogenic Heart Therapies

Nottingham – September 09, 2026 -- Isomab Ltd has published a systematic review showing no increased cancer or retinopathy risk from pro-angiogenic therapies for coronary artery disease, removing a two-decade safety barrier that has constrained development across the field.

Review of 636 patients finds malignancy rates below population norms

The analysis covered 11 clinical studies conducted between 2002 and 2024, spanning 636 patients with angina or peripheral artery disease -- 441 receiving pro-angiogenic therapy and 195 on placebo -- with follow-up periods ranging from two to 12 years. Mean malignancy incidence was 0.84 per 100 patient-years for the treatment group versus 0.72 for placebo, both figures falling below the age-matched population rate of 1.0 per 100 patient-years. Retinal events were rare in both cohorts and also below population benchmarks.